MTACU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTACU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
MedTech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.33 Mil. MedTech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. MedTech Acquisition's annualized EBITDA for the quarter that ended in Jun. 2023 was $-5.72 Mil. MedTech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.58.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for MedTech Acquisition's Debt-to-EBITDA or its related term are showing as below:
During the past 3 years, the highest Debt-to-EBITDA Ratio of MedTech Acquisition was -0.36. The lowest was -0.85. And the median was -0.60.
The historical data trend for MedTech Acquisition's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedTech Acquisition Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Debt-to-EBITDA | N/A | -0.36 | -0.85 |
MedTech Acquisition Quarterly Data | ||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
-1.25 | -0.95 | -0.43 | -0.89 | -0.58 |
For the Shell Companies subindustry, MedTech Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedTech Acquisition's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
MedTech Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.983 | + | 1.341) | / | -2.746 | |
= | -0.85 |
MedTech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (3.331 | + | 0) | / | -5.72 | |
= | -0.58 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.
MedTech Acquisition (NAS:MTACU) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of MedTech Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Magnetar Financial Llc | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Magnetar Capital Partners Lp | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Supernova Management Llc | 10 percent owner | 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David J. Snyderman | 10 percent owner | C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David L Treadwell | director | 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102 |
Manuel Aguero | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
Thierry B. Thaure | director | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
David J Matlin | director, 10 percent owner, officer: Chief Financial Officer | |
Karim Karti | director | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103 |
Christopher C Dewey | director, 10 percent owner, officer: Chief Executive Officer | 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271 |
Robert H. Weiss | officer: Chief Admin Officer and Sec. | 585 WEED STREET, NEW CANAAN CT 06840 |
Maurice R Ferre | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317 |
Ivan Delevic | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317 |
Medtech Acquisition Sponsor Llc | 10 percent owner | 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Martin William Roche | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 08-15-2023
By GuruFocusNews GuruFocusNews • 03-10-2022
By Business Wire Business Wire • 06-12-2023
By PRNewswire PRNewswire • 08-19-2021
By GuruFocus Research • 07-28-2023
By Business Wire • 08-02-2023
By PRNewswire PRNewswire • 08-13-2021
By Value_Insider Value_Insider • 12-08-2022
By GlobeNewswire GlobeNewswire • 12-08-2022
By Marketwired Marketwired • 12-23-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.